If you need more lookups,
subscriptions start at $34 USD/month.
Seng Cheng Location
Boston, MA, US
Seng Cheng Work
Senior Vice President, Research and Product Development @ (July 2023 - Present)
Senior Vice President and Chief Scientific Officer, Rare Disease Research Unit @ (July 2018 - July 2023)
Global Head of Research, Rare Diseases @ (January 2016 - July 2018)
Head of Research and Early Development, Rare Diseases Division @ (January 2011 - January 2016)
Group Vice President, Genetic Diseases Science @ (January 1989 - January 2011)
Staff Scientist @ Integrated Genetics (January 1985 - January 1989)
Postdoctoral Fellow @ (January 1983 - January 1985)
Seng Cheng Education
University of London
Ph.D. (Biochemistry)
1979-1983
University of London
B.Sc (Biochemistry)
1976-1979
Culford School
Chemistry (Physics and Mathematics)
1971-1976
Seng Cheng Skills
Biotechnology
Drug Development
Lifesciences
Genetics
Immunology
Oncology
Drug Discovery
Clinical Development
Biopharmaceuticals
Molecular Biology
Neuroscience
Cell Biology
Pharmaceutical Industry
Pharmacology
Cell
Clinical Trials
Science
In Vivo
Biochemistry
Protein Chemistry
In Vitro
Technology Transfer
Assay Development
Genomics
Commercialization
Purification
Cancer
High Throughput Screening
Immunoassays
Stem Cells
GLP
Protein Purification
ELISA
Western Blotting
Infectious Diseases
Vaccines
Biomarkers
Life Sciences
Gene Therapy
Scientific Management
Good Laboratory Practice (GLP)
Cross-functional Team Leadership
Seng Cheng Summary
Seng Cheng, based in Boston, MA, US, is currently a Senior Vice President, Research and Product Development at Alexion Pharmaceuticals, Inc.. Seng Cheng brings experience from previous roles at Pfizer, Sanofi and Genzyme. Seng Cheng holds a 1979 - 1983 Ph.D. in Biochemistry @ University of London. With a robust skill set that includes Biotechnology, Drug Development, Lifesciences, Genetics, Immunology and more. Seng Cheng has 4 emails and 4 mobile phone numbers on RocketReach.
Looking for a different Seng Cheng?
Find contact details for 700 million professionals.